CDXC ChromaDex Corp.: יחס שווי שוק לערך בספרים

ChromaDex Corporation (CDXC) produces innovative longevity supplements at its own US-based facilities, leveraging patents in cellular metabolism. The market cap to book value ratio reflects market expectations, where the value of 13.02 expresses the metric level. The Tru Niagen ecosystem and B2B NAD+ licenses ensure customer retention, while the defensive qualities of demand for nutritional products minimize the impact of inflation and macroeconomic risks.

This ratio is calculated as the market value of all shares relative to the total equity. The metric determines the premium investors are willing to pay per unit of the company's net assets. For ChromaDex Corporation (CDXC), this balance reflects the market valuation of Tru Niagen's sales potential relative to the company's actual resources. Low values ensure capital protection, while high values indicate inflated expectations. By tracking changes in the company's P/BV level, one can promptly assess the asset's investment attractiveness.